A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Lilly

Status and phase: Completed; Phase 2

Conditions: Non-Hodgkin's Lymphoma

Treatments: Drug: LY317615

Study type: Interventional

Funder types: Industry

Identifiers

NCT00042666

H6Q-MC-JCAI (Other Identifier)

4849

Details and patient eligibility

About

This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).

Enrollment: 55 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A diagnosis of recurrent or refractory DLBCL.
• Adequate organ functions.
• Able to swallow capsules.

Exclusion criteria

• More than 3 prior treatments for this disease.
• Serious heart problems.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

55 participants in 1 patient group

LY317615

Experimental group

Description:

500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles

Treatment:

Drug: LY317615